Toxoplasma gondii infection associated with inflammasome activation and neuronal injury.

Bipolar disorder Healthy controls Interleukin-18 Neuron-specific enolase Schizophrenia

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 Mar 2024
Historique:
received: 24 09 2023
accepted: 28 02 2024
medline: 5 3 2024
pubmed: 5 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

Toxoplasma gondii (TOXO) infection typically results in chronic latency due to its ability to form cysts in the brain and other organs. Latent toxoplasmosis could promote innate immune responses and impact brain function. A large body of evidence has linked TOXO infection to severe mental illness (SMI). We hypothesized that TOXO immunoglobulin G (IgG) seropositivity, reflecting previous infection and current latency, is associated with increased circulating neuron-specific enolase (NSE), a marker of brain damage, and interleukin-18 (IL-18), an innate immune marker, mainly in SMI. We included 735 patients with SMI (schizophrenia or bipolar spectrum) (mean age 32 years, 47% women), and 518 healthy controls (HC) (mean age 33 years, 43% women). TOXO IgG, expressed as seropositivity/seronegativity, NSE and IL-18 were measured with immunoassays. We searched for main and interaction effects of TOXO, patient/control status and sex on NSE and IL-18. In the whole sample as well as among patients and HC separately, IL-18 and NSE concentrations were positively correlated (p < 0.001). TOXO seropositive participants had significantly higher NSE (3713 vs. 2200 pg/ml, p < 0.001) and IL-18 levels (1068 vs. 674 pg/ml, p < 0.001) than seronegative participants, and evaluation within patients and HC separately showed similar results. Post-hoc analysis on cytomegalovirus and herpes simplex virus 1 IgG status showed no associations with NSE or IL-18 which may suggest TOXO specificity. These results may indicate ongoing inflammasome activation and neuronal injury in people with TOXO infections unrelated to diagnosis.

Identifiants

DOI: 10.1038/s41598-024-55887-9 PMID: 38438515
pubmed: 38438515
doi: 10.1038/s41598-024-55887-9
pii: 10.1038/s41598-024-55887-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5327

Subventions

Organisme : Norges Forskningsråd
ID : 223273
Organisme : South-Eastern Norway Regional Health Authority
ID : 2019-108

Informations de copyright

© 2024. The Author(s).

Références

Sullivan, W. J. Jr. & Jeffers, V. Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol. Rev. 36, 717–733. https://doi.org/10.1111/j.1574-6976.2011.00305.x (2012).
doi: 10.1111/j.1574-6976.2011.00305.x
McAuley, J. B. Congenital toxoplasmosis. J. Pediatr. Infect. Dis. Soc. 3(Suppl 1), S30-35. https://doi.org/10.1093/jpids/piu077 (2014).
doi: 10.1093/jpids/piu077
Tenter, A. M., Heckeroth, A. R. & Weiss, L. M. Toxoplasma gondii: From animals to humans. Int. J. Parasitol. 30, 1217–1258. https://doi.org/10.1016/s0020-7519(00)00124-7 (2000).
doi: 10.1016/s0020-7519(00)00124-7 pmcid: 3109627
Vieta, E. et al. Bipolar disorders. Nat. Rev. Dis. Primers 4, 18008. https://doi.org/10.1038/nrdp.2018.8 (2018).
doi: 10.1038/nrdp.2018.8
Kahn, R. S. et al. Schizophrenia. Nat. Rev. Dis. Primers 1, 15067. https://doi.org/10.1038/nrdp.2015.67 (2015).
doi: 10.1038/nrdp.2015.67
Hayes, J. F., Marston, L., Walters, K., King, M. B. & Osborn, D. P. J. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br. J. Psychiatry 211, 175–181. https://doi.org/10.1192/bjp.bp.117.202606 (2017).
doi: 10.1192/bjp.bp.117.202606 pmcid: 5579328
Costanza, A. et al. Demoralization in suicide: A systematic review. J. Psychosom. Res. 157, 110788. https://doi.org/10.1016/j.jpsychores.2022.110788 (2022).
doi: 10.1016/j.jpsychores.2022.110788
Sutterland, A. L. et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: Systematic review and meta-analysis. Acta Psychiatr. Scand. 132, 161–179. https://doi.org/10.1111/acps.12423 (2015).
doi: 10.1111/acps.12423
Sutterland, A. L. et al. Toxoplasma gondii infection and clinical characteristics of patients with schizophrenia: A systematic review and meta-analysis. Schizophrenia Bull. Open https://doi.org/10.1093/schizbullopen/sgaa042 (2020).
doi: 10.1093/schizbullopen/sgaa042
Del Grande, C., Galli, L., Schiavi, E., Dell’Osso, L. & Bruschi, F. Is Toxoplasma gondii a trigger of bipolar disorder?. Pathogens https://doi.org/10.3390/pathogens6010003 (2017).
doi: 10.3390/pathogens6010003 pmcid: 5371891
Latz, E., Xiao, T. S. & Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397–411. https://doi.org/10.1038/nri3452 (2013).
doi: 10.1038/nri3452
Gorfu, G. et al. Dual role for inflammasome sensors NLRP1 and NLRP3 in murine resistance to Toxoplasma gondii. mBio https://doi.org/10.1128/mBio.01117-13 (2014).
doi: 10.1128/mBio.01117-13 pmcid: 3944820
Szabo, A. et al. Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation. Brain Behav. Immunol. 99, 299–306. https://doi.org/10.1016/j.bbi.2021.10.017 (2022).
doi: 10.1016/j.bbi.2021.10.017
Marangos, P. J. & Schmechel, D. E. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci. 10, 269–295. https://doi.org/10.1146/annurev.ne.10.030187.001413 (1987).
doi: 10.1146/annurev.ne.10.030187.001413
Isgro, M. A., Bottoni, P. & Scatena, R. Neuron-specific enolase as a biomarker: Biochemical and clinical aspects. Adv. Exp. Med. Biol. 867, 125–143. https://doi.org/10.1007/978-94-017-7215-0_9 (2015).
doi: 10.1007/978-94-017-7215-0_9
Haque, A., Polcyn, R., Matzelle, D. & Banik, N. L. New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection. Brain Sci. https://doi.org/10.3390/brainsci8020033 (2018).
doi: 10.3390/brainsci8020033 pmcid: 5836052
Cheng, F., Yuan, Q., Yang, J., Wang, W. & Liu, H. The prognostic value of serum neuron-specific enolase in traumatic brain injury: Systematic review and meta-analysis. PLoS One 9, e106680. https://doi.org/10.1371/journal.pone.0106680 (2014).
doi: 10.1371/journal.pone.0106680 pmcid: 4154726
Dincel, G. C. & Atmaca, H. T. Role of oxidative stress in the pathophysiology of Toxoplasma gondii infection. Int. J. Immunopathol. Pharmacol. 29, 226–240. https://doi.org/10.1177/0394632016638668 (2016).
doi: 10.1177/0394632016638668 pmcid: 5806720
Sasai, M. & Yamamoto, M. Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection. Exp. Mol. Med. 51, 1–10. https://doi.org/10.1038/s12276-019-0353-9 (2019).
doi: 10.1038/s12276-019-0353-9
Wohlfert, E. A., Blader, I. J. & Wilson, E. H. Brains and brawn: Toxoplasma infections of the central nervous system and skeletal muscle. Trends Parasitol. 33, 519–531. https://doi.org/10.1016/j.pt.2017.04.001 (2017).
doi: 10.1016/j.pt.2017.04.001 pmcid: 5549945
First, M. B., Spitzer, R. L., Gibbon, M. & Williams, J. B. Structured clinical interview for DSM-IV axis I disorders (SCIDI), clinician version, administration booklet. (American Psychiatric Association Publishing, 2012).
Spitzer, R. L. et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 272, 1749–1756 (1994).
doi: 10.1001/jama.1994.03520220043029
Galobardes, B., Shaw, M., Lawlor, D. A., Lynch, J. W. & Davey Smith, G. Indicators of socioeconomic position (part 1). J. Epidemiol. Community Health 60, 7–12. https://doi.org/10.1136/jech.2004.023531 (2006).
doi: 10.1136/jech.2004.023531 pmcid: 2465546
Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D. & Ho, B. C. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol. Psychiatry 67, 255–262. https://doi.org/10.1016/j.biopsych.2009.08.040 (2010).
doi: 10.1016/j.biopsych.2009.08.040
Dickerson, F. B. et al. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch. Gen. Psychiatry 60, 466–472. https://doi.org/10.1001/archpsyc.60.5.466 (2003).
doi: 10.1001/archpsyc.60.5.466
Dickerson, F. et al. Association between cytomegalovirus antibody levels and cognitive functioning in non-elderly adults. PLoS One 9, e95510. https://doi.org/10.1371/journal.pone.0095510 (2014).
doi: 10.1371/journal.pone.0095510 pmcid: 4028176
Yolken, R. H. et al. Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin. Infect. Dis. 32, 842–844. https://doi.org/10.1086/319221 (2001).
doi: 10.1086/319221
Wang, H., Yolken, R. H., Hoekstra, P. J., Burger, H. & Klein, H. C. Antibodies to infectious agents and the positive symptom dimension of subclinical psychosis: The TRAILS study. Schizophr. Res. 129, 47–51. https://doi.org/10.1016/j.schres.2011.03.013 (2011).
doi: 10.1016/j.schres.2011.03.013
Andreou, D. et al. Lower circulating neuron-specific enolase concentrations in adults and adolescents with severe mental illness. Psychol. Med. 20, 1–10 (2021).
Beyerlein, A. Quantile regression-opportunities and challenges from a user’s perspective. Am. J. Epidemiol. 180, 330–331. https://doi.org/10.1093/aje/kwu178 (2014).
doi: 10.1093/aje/kwu178
Cheon, S. Y., Kim, J., Kim, S. Y., Kim, E. J. & Koo, B. N. Inflammasome and cognitive symptoms in human diseases: Biological evidence from experimental research. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21031103 (2020).
doi: 10.3390/ijms21031103 pmcid: 7765524
Iwata, M., Ota, K. T. & Duman, R. S. The inflammasome: Pathways linking psychological stress, depression, and systemic illnesses. Brain Behav. Immunol. 31, 105–114. https://doi.org/10.1016/j.bbi.2012.12.008 (2013).
doi: 10.1016/j.bbi.2012.12.008
Kaufmann, F. N. et al. NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. Brain Behav. Immunol. 64, 367–383. https://doi.org/10.1016/j.bbi.2017.03.002 (2017).
doi: 10.1016/j.bbi.2017.03.002
Berardelli, I. et al. The involvement of hypothalamus–pituitary–adrenal (HPA) axis in suicide risk. Brain Sci. https://doi.org/10.3390/brainsci10090653 (2020).
doi: 10.3390/brainsci10090653 pmcid: 7565104
Papuc, E. & Rejdak, K. Increased cerebrospinal fluid S100B and NSE reflect neuronal and glial damage in Parkinson’s disease. Front. Aging Neurosci. 12, 156. https://doi.org/10.3389/fnagi.2020.00156 (2020).
doi: 10.3389/fnagi.2020.00156 pmcid: 7387568
Cai, G., Kastelein, R. & Hunter, C. A. Interleukin-18 (IL-18) enhances innate IL-12-mediated resistance to Toxoplasma gondii. Infect. Immunol. 68, 6932–6938. https://doi.org/10.1128/IAI.68.12.6932-6938.2000 (2000).
doi: 10.1128/IAI.68.12.6932-6938.2000
Dupont, L. & Reeves, M. B. Cytomegalovirus latency and reactivation: Recent insights into an age old problem. Rev. Med. Virol. 26, 75–89. https://doi.org/10.1002/rmv.1862 (2016).
doi: 10.1002/rmv.1862
Wills, M. R., Poole, E., Lau, B., Krishna, B. & Sinclair, J. H. The immunology of human cytomegalovirus latency: Could latent infection be cleared by novel immunotherapeutic strategies?. Cell Mol. Immunol. 12, 128–138. https://doi.org/10.1038/cmi.2014.75 (2015).
doi: 10.1038/cmi.2014.75
Duarte, L. F. et al. Herpes simplex virus Type 1 infection of the central nervous system: Insights into proposed interrelationships with neurodegenerative disorders. Front. Cell. Neurosci. 13, 46. https://doi.org/10.3389/fncel.2019.00046 (2019).
doi: 10.3389/fncel.2019.00046 pmcid: 6399123
Andreou, D. et al. Cytomegalovirus infection associated with smaller dentate gyrus in men with severe mental illness. Brain Behav. Immunol. https://doi.org/10.1016/j.bbi.2021.05.009 (2021).
doi: 10.1016/j.bbi.2021.05.009
Andreou, D. et al. Cytomegalovirus infection and IQ in patients with severe mental illness and healthy individuals. Psychiatry Res. 300, 113929. https://doi.org/10.1016/j.psychres.2021.113929 (2021).
doi: 10.1016/j.psychres.2021.113929
Andreou, D. et al. Cytomegalovirus infection associated with smaller total cortical surface area in Schizophrenia spectrum disorders. Schizophr. Bull. https://doi.org/10.1093/schbul/sbac036 (2022).
doi: 10.1093/schbul/sbac036 pmcid: 9212107
Tucker, J. D. & Bertke, A. S. Assessment of cognitive impairment in HSV-1 positive schizophrenia and bipolar patients: Systematic review and meta-analysis. Schizophr. Res. 209, 40–47. https://doi.org/10.1016/j.schres.2019.01.001 (2019).
doi: 10.1016/j.schres.2019.01.001
Prasad, K. M. et al. Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: A longitudinal study. Am. J. Psychiatry 168, 822–830. https://doi.org/10.1176/appi.ajp.2011.10101423 (2011).
doi: 10.1176/appi.ajp.2011.10101423 pmcid: 4209378
Andreou, D. et al. Herpes simplex virus 1 infection on grey matter and general intelligence in severe mental illness. Transl. Psychiatry 12, 276. https://doi.org/10.1038/s41398-022-02044-3 (2022).
doi: 10.1038/s41398-022-02044-3 pmcid: 9276804

Auteurs

Dimitrios Andreou (D)

Department of Psychiatric Research, Diakonhjemmet Hospital, Forskningsveien 7, 0373, Oslo, Norway. dimitrios.andreou@ki.se.
Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway. dimitrios.andreou@ki.se.
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden. dimitrios.andreou@ki.se.

Nils Eiel Steen (NE)

Department of Psychiatric Research, Diakonhjemmet Hospital, Forskningsveien 7, 0373, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Lynn Mørch-Johnsen (L)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Psychiatry and Department of Clinical Research, Østfold Hospital, Grålum, Norway.

Kjetil Nordbø Jørgensen (KN)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Division of Mental Health and Addiction, Vestre Viken Hospital Trust, Drammen, Norway.

Laura A Wortinger (LA)

Department of Psychiatric Research, Diakonhjemmet Hospital, Forskningsveien 7, 0373, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Claudia Barth (C)

Department of Psychiatric Research, Diakonhjemmet Hospital, Forskningsveien 7, 0373, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Attila Szabo (A)

Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.

Kevin S O'Connell (KS)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Tove Lekva (T)

Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Gabriela Hjell (G)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Psychiatry and Department of Clinical Research, Østfold Hospital, Grålum, Norway.

Ingrid Torp Johansen (IT)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Monica B E G Ormerod (MBEG)

Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Unn K Haukvik (UK)

Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.
Department of Forensic Research and Education, Oslo University Hospital, Oslo, Norway.

Pål Aukrust (P)

Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Srdjan Djurovic (S)

Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Bergen, Norway.

Robert H Yolken (RH)

Stanley Division of Developmental Neurovirology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Ole A Andreassen (OA)

Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.

Thor Ueland (T)

Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Thrombosis Research Center (TREC), Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway.

Ingrid Agartz (I)

Department of Psychiatric Research, Diakonhjemmet Hospital, Forskningsveien 7, 0373, Oslo, Norway.
Norwegian Centre for Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet and Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.

Classifications MeSH